Lifeward's ReWalk Exoskeleton Shows Zero Fractures in German Users Since 2018

Event summary

  • Lifeward presented new ReWalk exoskeleton data at the ASIA 2026 conference, showing zero fractures among 97 German users since 2018.
  • Global fracture prevalence declined from 3% to 0.3% over the past six years (2020–2025).
  • The study analyzed over a decade of real-world data, reinforcing the safety profile of the ReWalk exoskeleton.
  • Lifeward CEO Mark Grant highlighted the importance of these findings for broader adoption of ReWalk as a standard of care option.

The big picture

Lifeward's data presentation at the ASIA 2026 conference underscores the growing clinical consensus that exoskeleton-assisted walking can be both effective and safe. The near elimination of fractures in recent years supports the broader adoption of ReWalk, positioning it as a key player in the spinal cord injury mobility market. The findings also highlight the importance of refined patient and provider training in achieving better outcomes for patients.

What we're watching

Safety Profile
Whether the sustained improvement in safety outcomes will accelerate regulatory approvals and reimbursement for ReWalk.
Market Adoption
The pace at which clinicians and patients adopt ReWalk as a standard of care for spinal cord injury mobility.
Technological Advancements
How continued advancements in device technology and training protocols will further reduce adverse events.